Comparison · NCT00032487-6ac6ebfb
Arm 1 vs Arm 2: Primary Major Macrovascular Events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm 1 vs Arm 2: Primary Major Macrovascular Events. Trial comparisons, record NCT00032487-6ac6ebfb. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00032487-6ac6ebfb
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.294 | 0.265 | 0.324 | wilson | |
| Risk in group 2 | 0.263 | 0.236 | 0.293 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0302 | -0.0113 | 0.0716 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.11 | 0.96 | 1.29 | log | |
| Odds ratio, group 1 over group 2 | 1.16 | 0.945 | 1.43 | log | |
| Number needed to treat, for one more participant with the outcome on Arm 1 than on Arm 2 | 33.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm 1 | Standard glycemic control to maintain HbA1c between 8.0-9.0%. Metformin 500 mg Rosiglitazone 4 mg Glimepiride 2 mg Insulin 1 unit 9 lbs | 264 | 899 | OG000 |
| Group 2 | Arm 2 | Intensive glycemic control lower HbA1c below 6.0%. Metformin 500 mg (go up to 2000 mg) Rosiglitazone 4 mg bid Glimepiride 8 mg Insulin 1 unit 9 lbs add one injection to Arm 1 | 235 | 892 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Primary Major Macrovascular Events
- Description
Myocardial infarction (MI), intervention for coronary artery or Peripheral Vascular Disease (PVD), severe inoperable Coronary Artery Disease (CAD), new or worsening Congestive Heart Failure (CHF), stroke, Cardiovascular (CV) death, or amputation for ischemic gangrene.
- Time frame
- Post baseline time to the first major macrovascular event up to 82 months
- Population
Source ClinicalTrials.gov
Trial
- Title
- Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)
- NCT number
- NCT00032487
- Phases
- PHASE3
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Insulin, Glimepiride, Rosiglitazone, Metformin
- Lead sponsor
- VA Office of Research and Development
- Results first posted
- 2014-02-12
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00032487?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00032487-6ac6ebfb